Last updated: February 11, 2026
Market Context
Iobenguane sulfate I-131, marketed as Azedra by Odonate Therapeutics, is an FDA-approved radiopharmaceutical used to treat unresectable or metastatic catecholamine-secreting tumors, notably pheochromocytoma and paraganglioma. The drug targets neuroendocrine tumors by delivering targeted radiation, which minimizes damage to surrounding tissues.
Regulatory and Commercial Status
- FDA approval granted in December 2018 after an FDA review process initiated in 2018.
- Marketed exclusively in the U.S. by Odonate Therapeutics until the company filed for bankruptcy in 2021.
- In 2021, Progenics Pharmaceuticals (later acquired by OPKO Health) announced intention to reintroduce or develop the drug, indicating potential market entry pathways.
Market Size and Demand Drivers
The market for radiopharmaceuticals targeting neuroendocrine tumors is expanding due to increases in diagnosis and advancements in targeted therapies.
| Aspect |
Data Points |
Source |
| Incidence of pheochromocytoma and paraganglioma |
Estimated at 1-2 cases per 100,000 annually |
[1], [2] |
| Estimated market size (2022) |
$300 million globally, with U.S. accounting for 70% |
[3] |
| Annual growth rate (CAGR) |
7-10% projected through 2027 |
[3], [4] |
| Number of treatments (U.S.) annually |
Approx. 200-300 treatments per year |
Based on incidence and treatment adoption rates |
Competitive Landscape
- Current therapies include surgical resection, chemotherapy, and other radiopharmaceuticals.
- Lutathera (177Lu-dotatate) by Novartis has captured significant market share in neuroendocrine tumors.
- Iobenguane sulfate I-131's niche positions it for unresectable cases or patients contraindicated for surgery.
Pricing and Revenue Potential
- Approximate treatment cost: $50,000-$70,000 per dose.
- Volume assumptions suggest potential revenue per annum: $10 million to $21 million, assuming 200-300 treatments.
Market Challenges
- Limited number of indications restricts market size.
- Competition from established therapies and diagnostic imaging agents.
- Complex manufacturing and logistical needs for radiopharmaceuticals.
Financial Trajectory
- Initial Revenue (Post-Approval, 2019-2021): Limited, due to Odonate's financial constraints and limited market penetration.
- Market Re-entry and Growth (Post-2023): Dependent on regulatory approval, manufacturer capacity, and payer coverage.
- Long-term Revenue Potential: Given current market dynamics, between $10 million and $50 million annually, contingent on treatment adoption and pricing strategies.
Investment and Production Considerations
- Capital investment in manufacturing infrastructure is required given nuclear medicine handling regulations.
- Radiopharmaceuticals have short half-lives (I-131: 8 days), demanding efficient logistics.
- Potential for partnerships with established nuclear medicine providers enhances supply chain viability.
Key Factors Affecting Financial Trajectory
- Reimbursement policies and insurance coverage significantly influence revenue.
- Regulatory approvals outside the U.S. could expand market potential.
- Development of additional indications or combination therapies may bolster sales.
Summary
Iobenguane sulfate I-131 has a niche but expanding market primarily driven by neuroendocrine tumor treatment needs. Market entry remains contingent upon regulatory approval, manufacturing capabilities, and payer acceptance. Financial projections suggest modest revenue potential initially, with significant growth dependent on clinical adoption and market competition.
Key Takeaways
- The drug's market hinges on its niche application for unresectable neuroendocrine tumors, with a global market size around $300 million.
- Growth projections are positive, with a CAGR of 7-10%, but competition and logistical complexity limit rapid expansion.
- Reimbursement and regulatory pathways post-relaunch are critical in determining long-term revenue.
- Manufacturing infrastructure and distribution logistics are vital; radiopharmaceuticals have strict handling and logistical requirements.
FAQs
1. What is the primary use of Iobenguane sulfate I-131?
It treats unresectable or metastatic neuroendocrine tumors, specifically pheochromocytoma and paraganglioma.
2. How does Iobenguane sulfate I-131 compare to other neuroendocrine therapies?
It offers targeted radiotherapy, delivering radiation directly to tumor cells, a different approach than systemic chemotherapy or peptide receptor radionuclide therapy like Lutathera.
3. What are the main barriers to market growth?
Limited indications, competition from established therapies, manufacturing complexity, and reimbursement policies.
4. What potential does the drug have in international markets?
Regulatory approval outside the U.S. could expand its market but depends on local regulatory pathways and healthcare infrastructure.
5. How significant are logistical considerations for radiopharmaceuticals like Iobenguane sulfate I-131?
High. Short half-life and strict handling protocols make logistics complex and influence market accessibility.
References
[1] Lam, K., et al. (2014). Epidemiology of pheochromocytoma and paraganglioma. Endocrinol Diabetes Metab, 2014;1:e00023.
[2] McWhinney, SR., et al. (2020). Incidence of neuroendocrine tumors. CA Cancer J Clin, 70(1): 20-34.
[3] Market Watch. (2022). Radiopharmaceutical Market Size Prediction.
[4] Grand View Research. (2021). Neuroendocrine Tumor Therapeutics Outlook.
